David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$397M |
| 2 |
YHOO
Yahoo Inc
YHOO
|
+$342M |
| 3 |
Bank of America
BAC
|
+$322M |
| 4 |
Citigroup
C
|
+$260M |
| 5 |
Booking.com
BKNG
|
+$219M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$637M |
| 2 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$397M |
| 3 |
Gilead Sciences
GILD
|
+$358M |
| 4 |
Phillips 66
PSX
|
+$330M |
| 5 |
Apple
AAPL
|
+$320M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.78% |
| 2 | Technology | 11.11% |
| 3 | Financials | 10% |
| 4 | Consumer Discretionary | 8.83% |
| 5 | Communication Services | 8.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2976
Independent Bank
INDB
$3.95B
| $311K | ﹤0.01% |
+6,767
| New | +$302K |
|
2977
PUT
Ovintiv
OVV
$18.2B
| $311K | ﹤0.01% |
10,200
-20,000
| -66% | -$460K |
|
|
DVAX
2978
CALL
DELISTED
Dynavax Technologies
DVAX
| $308K | ﹤0.01% |
16,000
| – | – |
|
2979
Inovio Pharmaceuticals
INO
$129M
| $307K | ﹤0.01% |
2,939
-2,797
| -49% | -$216K |
|
2980
CALL
XPO
XPO
$22.5B
| $307K | ﹤0.01% |
28,914
| – | – |
|
2981
PUT
Nu Skin
NUS
$232M
| $306K | ﹤0.01% |
8,000
-10,000
| -56% | -$331K |
|
|
DRE
2982
DELISTED
Duke Realty Corp.
DRE
| $302K | ﹤0.01% |
13,395
| – | – |
|
2983
Freshpet
FRPT
$3.68B
| $301K | ﹤0.01% |
+41,042
| New | +$286K |
|
2984
Seacoast Banking Corp of Florida
SBCF
$3.32B
| $301K | ﹤0.01% |
19,077
-24,130
| -56% | -$357K |
|
2985
Fulton Financial
FULT
$4.5B
| $300K | ﹤0.01% |
22,387
-42,829
| -66% | -$546K |
|
|
NGHC
2986
DELISTED
National General Holdings Corp
NGHC
| $300K | ﹤0.01% |
13,912
-31,197
| -69% | -$629K |
|
2987
CALL
NCR Voyix
VYX
$1.1B
| $299K | ﹤0.01% |
16,300
| – | – |
|
2988
Extra Space Storage
EXR
$30.9B
| $296K | ﹤0.01% |
3,162
| – | – |
|
2989
Matador Resources
MTDR
$7.12B
| $295K | ﹤0.01% |
15,566
-93,380
| -86% | -$1.55M |
|
|
AVH
2990
DELISTED
AVIANCA HOLDINGS S.A.
AVH
| $295K | ﹤0.01% |
59,324
+35,912
| +153% | +$158K |
|
|
FWP
2991
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $295K | ﹤0.01% |
2,482
-234
| -9% | -$26.2K |
|
2992
PUT
Puma Biotechnology
PBYI
$471M
| $294K | ﹤0.01% |
10,000
-100
| -1% | -$4.52K |
|
2993
Prudential Financial
PRU
$42.3B
| $294K | ﹤0.01% |
4,066
-18,878
| -82% | -$1.32M |
|
2994
Sun Communities
SUI
$15B
| $294K | ﹤0.01% |
4,108
-6,937
| -63% | -$468K |
|
2995
Agios Pharmaceuticals
AGIO
$1.95B
| $293K | ﹤0.01% |
7,227
-4,938
| -41% | -$211K |
|
|
ESGR
2996
DELISTED
Enstar Group
ESGR
| $293K | ﹤0.01% |
+1,802
| New | +$279K |
|
2997
Fidus Investment
FDUS
$752M
| $293K | ﹤0.01% |
18,867
-3,261
| -15% | -$45K |
|
2998
Lee Enterprises
LEE
$184M
| $293K | ﹤0.01% |
16,298
-2,703
| -14% | -$42.3K |
|
2999
PetMed Express
PETS
$37.9M
| $293K | ﹤0.01% |
16,357
-662
| -4% | -$11.3K |
|
3000
Dominion Energy
D
$58.6B
| $292K | ﹤0.01% |
+3,886
| New | +$275K |
|
Similar funds
David Shaw's Q1 2016 Portfolio in Review
As of Q1 2016, David Shaw held 4,137 positions worth $55.7B, down 17% from $67.2B the previous quarter. Its ten largest holdings account for 9.5% of the portfolio.
David Shaw withdrew a net $9.72B in Q1 2016, closing 773 positions and reducing 1,495 holdings. Its most notable exit was PRECISION CASTPARTS CORP, an estimated $637M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, up from 13% a quarter earlier, followed by Technology and Financials.
Against the trend, David Shaw opened a new position in EQT Corp worth $47.6M.
- David Shaw's largest Q1 2016 buy was EQT Corp: 1,300,361 shares worth $47.6M.
- David Shaw added most to Allergan plc in Q1 2016, an estimated $397M increase.
- David Shaw's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $358M.
- David Shaw fully exited PRECISION CASTPARTS CORP in Q1 2016, selling an estimated $637M.
- David Shaw's ten largest holdings make up 9.5% of its $55.7B portfolio in Q1 2016.
- David Shaw opened 382 new positions and closed 773 in Q1 2016.
- David Shaw's portfolio value fell 17% quarter-over-quarter to $55.7B.
Based on D.E. Shaw & Co's 13F filing for Q1 2016, filed 16 May 2016.